pembrolizumab,pds0101
pds biotech,merck
['keytruda', 'pds bio', '$pdsb']
$pdsb is up 10.41% as pds biotech prepares to discuss interim data from versatile-002 phase 2 clinical trial with keytruda at asco meeting tomorrow. 
Stock Market Trader - Follow your own opinions